Cargando…

PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment

PHY906 (KD018) is a four-herb Chinese Medicine Formula. It has been shown to potentially enhance the therapeutic indices of different class anticancer agents in vivo. Here, PHY906 is reported to enhance the anti-tumor activity of Sorafenib in nude mice bearing HepG2 xenografts. Among the four herbal...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Wing, Jiang, Zaoli, Guan, Fulan, Huang, Xiu, Hu, Rong, Wang, Jing, Bussom, Scott, Liu, Shwu-Huey, Zhao, Hongyu, Yen, Yun, Cheng, Yung-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377583/
https://www.ncbi.nlm.nih.gov/pubmed/25819872
http://dx.doi.org/10.1038/srep09384
_version_ 1782363938768289792
author Lam, Wing
Jiang, Zaoli
Guan, Fulan
Huang, Xiu
Hu, Rong
Wang, Jing
Bussom, Scott
Liu, Shwu-Huey
Zhao, Hongyu
Yen, Yun
Cheng, Yung-Chi
author_facet Lam, Wing
Jiang, Zaoli
Guan, Fulan
Huang, Xiu
Hu, Rong
Wang, Jing
Bussom, Scott
Liu, Shwu-Huey
Zhao, Hongyu
Yen, Yun
Cheng, Yung-Chi
author_sort Lam, Wing
collection PubMed
description PHY906 (KD018) is a four-herb Chinese Medicine Formula. It has been shown to potentially enhance the therapeutic indices of different class anticancer agents in vivo. Here, PHY906 is reported to enhance the anti-tumor activity of Sorafenib in nude mice bearing HepG2 xenografts. Among the four herbal ingredients of PHY906, Scutellaria baicalensis Georgi (S) and Paeonia lactiflora Pall (P) are required; however, S plays a more important role than P in increasing tumor apoptosis induced by Sorafenib with an increase of mouse(m)FasL and human(h)FasR expression. PHY906 may potentiate Sorafenib action by increasing hMCP1 expression and enhancing infiltration of macrophages into tumors with a higher M1/M2 (tumor rejection) signature expression pattern, as well as affect autophagy by increasing AMPKα-P and ULK1-S555-P of tumors. Depletion of macrophage could counteract PHY906 to potentiate the anti-tumor activity of Sorafenib. It was reported that tumor cells with higher levels of ERK1/2-P are more susceptible to Sorafenib, and the S component of PHY906 may increase ERK1/2-P via inhibition of ERK1/2 phosphatase in HepG2 tumors. PHY906 may potentiate the anti-hepatoma activity of Sorafenib by multiple mechanisms targeting on the inflammatory state of microenvironment of tumor tissue through two major ingredients (P and S) of PHY906.
format Online
Article
Text
id pubmed-4377583
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-43775832015-04-07 PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment Lam, Wing Jiang, Zaoli Guan, Fulan Huang, Xiu Hu, Rong Wang, Jing Bussom, Scott Liu, Shwu-Huey Zhao, Hongyu Yen, Yun Cheng, Yung-Chi Sci Rep Article PHY906 (KD018) is a four-herb Chinese Medicine Formula. It has been shown to potentially enhance the therapeutic indices of different class anticancer agents in vivo. Here, PHY906 is reported to enhance the anti-tumor activity of Sorafenib in nude mice bearing HepG2 xenografts. Among the four herbal ingredients of PHY906, Scutellaria baicalensis Georgi (S) and Paeonia lactiflora Pall (P) are required; however, S plays a more important role than P in increasing tumor apoptosis induced by Sorafenib with an increase of mouse(m)FasL and human(h)FasR expression. PHY906 may potentiate Sorafenib action by increasing hMCP1 expression and enhancing infiltration of macrophages into tumors with a higher M1/M2 (tumor rejection) signature expression pattern, as well as affect autophagy by increasing AMPKα-P and ULK1-S555-P of tumors. Depletion of macrophage could counteract PHY906 to potentiate the anti-tumor activity of Sorafenib. It was reported that tumor cells with higher levels of ERK1/2-P are more susceptible to Sorafenib, and the S component of PHY906 may increase ERK1/2-P via inhibition of ERK1/2 phosphatase in HepG2 tumors. PHY906 may potentiate the anti-hepatoma activity of Sorafenib by multiple mechanisms targeting on the inflammatory state of microenvironment of tumor tissue through two major ingredients (P and S) of PHY906. Nature Publishing Group 2015-03-30 /pmc/articles/PMC4377583/ /pubmed/25819872 http://dx.doi.org/10.1038/srep09384 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Lam, Wing
Jiang, Zaoli
Guan, Fulan
Huang, Xiu
Hu, Rong
Wang, Jing
Bussom, Scott
Liu, Shwu-Huey
Zhao, Hongyu
Yen, Yun
Cheng, Yung-Chi
PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
title PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
title_full PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
title_fullStr PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
title_full_unstemmed PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
title_short PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
title_sort phy906(kd018), an adjuvant based on a 1800-year-old chinese medicine, enhanced the anti-tumor activity of sorafenib by changing the tumor microenvironment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377583/
https://www.ncbi.nlm.nih.gov/pubmed/25819872
http://dx.doi.org/10.1038/srep09384
work_keys_str_mv AT lamwing phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment
AT jiangzaoli phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment
AT guanfulan phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment
AT huangxiu phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment
AT hurong phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment
AT wangjing phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment
AT bussomscott phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment
AT liushwuhuey phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment
AT zhaohongyu phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment
AT yenyun phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment
AT chengyungchi phy906kd018anadjuvantbasedona1800yearoldchinesemedicineenhancedtheantitumoractivityofsorafenibbychangingthetumormicroenvironment